Make a switch to monthly GLP-1 injection with the Vesper-Switch study

If you are currently taking Semaglutide or Tirzepetide injections and interested in switching to monthly doses for weight management - take part in a Vesper-Switch study!

You may be eligible if you meet all of below:

• 18 years old or above
• Currently taking injectable semaglutide ( also known as Ozempic or Wegovy) or injectable tirzepatide (also known as Zepbound) for weight loss
• Have been on the same dose for at least 3 months
• Have a BMI of at least 22 kg/m2
• Do not have Type 1 or type 2 Diabetes

There are other requirements to participate.

This Phase 3 study aims to find out if switching to monthly doses of Investigational study drug can help people keep their weight off over time. Every participant in the clinical trial will receive active treatment whether it is investigational study medicine or continuing their current approved weight management therapy (semaglutide or tirzepatide).

Participants will receive diet and exercise counseling throughout the study period and will be compensated for study visits.

To learn more please contact: This email address is being protected from spambots. You need JavaScript enabled to view it. or call:

Shruti – (205) 934-4980

or

MC - (205) 975-8217